Get the Facts and Tools You Need to Help Support Your Patients Receiving DARZALEX®

Share

DARZALEX® (daratumumab)
Redefining approaches in early lines of multiple myeloma

DARZALEX® (daratumumab) has proven efficacy and safety across multiple regimens and lines of therapy1

Newly diagnosed,
transplant-ineligible

DARZALEX® + Rd

(lenalidomide + dexamethasone)

EXPLORE STUDY

DARZALEX® + VMP

(bortezomib + melphalan + prednisone)

EXPLORE STUDY

After 1 prior therapy

DARZALEX® + Rd

(lenalidomide + dexamethasone)

EXPLORE STUDY

DARZALEX® + Vd

(bortezomib + dexamethasone)

EXPLORE STUDY

After ≥2 prior therapies

DARZALEX® + Pd*

(pomalidomide + dexamethasone)

*Prior therapies included lenalidomide and a proteasome inhibitor (PI).

EXPLORE STUDY

DARZALEX® monotherapy

Prior therapies included a PI and an immunomodulatory agent, or patients were double-refractory to a PI and an immunomodulatory agent.

EXPLORE STUDY